BAYER PHARMA AKTIENGESELLSCHAFT;BAYER HEALTHCARE PHARMACEUTICALS INC.
发明人:
申请号：
IL25416817
公开号：
IL254168D0
申请日:
2017.08.27
申请国别(地区):
IL
年份:
2017
代理人:
摘要：
The present invention relates to: use of a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or of a pharmaceutical composition containing same, as a sole active agent, or of a combination of a) said compound or a pharmaceutical composition containing said compound and b) one or more further active agents, for the preparation of a medicament for the treatment or prophylaxis of endometrial cancer (hereinafter abbreviated to “EC”), particularly 1st line, 2nd line, relapsed, refractory, type I or type II EC, or endometriosis； combinations of a) said compound and b) one or more further active agents； a pharmaceutical composition comprising said compound as a sole active agent for the treatment of endometrial cancer (hereinafter abbreviated to “EC”), particularly 1st line, 2nd line, relapsed, refractory, type I or type II EC, or endometriosis； a pharmaceutical composition comprising a combination of a) said compound and b) one or more further active agents； use of biomarkers which is the loss of tumor suppressor PTEN or FBXW7, for predicting the sensitivity and/or resistance of a cancer patient to said compound and providing a rationale-based dosage to increase sensitivity and/or to overcome resistance； a method of determining the loss of tumor suppressor PTEN or FBXW7； and a method for determining perturbations in PIK3CA, PIK3CB, PIK3CD, PIK3CG, P1K3R1, PIK3R2, PIK3R3, PIK3R4, PIK3R5, FGFR1, FGFR2, FGFR3 and/or FGFR4.
